

SUPPLEMENTARY TABLES

Supplementary Table 1. Expression of *ARHGAP30* mRNA in different subgroups.

Comparison	Statistical significance	Comparison	Statistical significance
Sample types		Age(21-40Yrs)-vs-Age(81-100Yrs)	2.99E-01
Normal-vs-Primary	1.62E-12	Age(41-60Yrs)-vs-Age(61-80Yrs)	2.83E-01
Individual cancer stages		Age(41-60Yrs)-vs-Age(81-100Yrs)	6.00E-02
Normal-vs-Stage1	1.11E-16	Age(61-80Yrs)-vs-Age(81-100Yrs)	1.18E-01
Normal-vs-Stage2	1.11E-16	Patient's smoking habit	
Normal-vs-Stage3	1.62E-12	Normal-vs-Non smoker	1.34E-11
Normal-vs-Stage4	1.66E-13	Normal-vs-Smoker	<1E-12
Stage1-vs-Stage2	2.62E-01	Normal-vs-Reformed smoker1	1.62E-12
Stage1-vs-Stage3	2.19E-04	Normal-vs-Reformed smoker2	<1E-12
Stage1-vs-Stage4	1.71E-02	Non smoker-vs-Smoker	2.04E-01
Stage2-vs-Stage3	3.79E-02	Non smoker-vs-Reformed smoker1	4.57E-01
Stage2-vs-Stage4	1.30E-01	Non smoker-vs-Reformed smoker2	2.59E-01
Stage3-vs-Stage4	9.91E-01	Smoker-vs-Reformed smoker1	5.14E-01
Patient's race		Smoker-vs-Reformed smoker2	6.98E-01
Normal-vs-Caucasian	1.62E-12	Reformed smoker1-vs-Reformed smoker2	7.22E-01
Normal-vs-African American	1.75E-12	Nodal metastasis status	
Normal-vs-Asian	9.72E-07	Normal-vs-N0	1.62E-12
Caucasian-vs-African American	3.96E-01	Normal-vs-N1	<1E-12
Caucasian-vs-Asian	1.38E-01	Normal-vs-N2	<1E-12
African American-vs-Asian	2.29E-01	Normal-vs-N3	5.83E-02
Patient's gender		N0-vs-N1	1.20E-01
Normal-vs-Male	1.11E-16	N0-vs-N2	1.28E-03
Normal-vs-Female	<1E-12	N0-vs-N3	9.73E-01
Male-vs-Female	1.78E-02	N1-vs-N2	2.39E-01
Patient's age		N1-vs-N3	8.20E-01
Normal-vs-Age(21-40Yrs)	1.54E-03	N2-vs-N3	5.56E-01
Normal-vs-Age(41-60Yrs)	1.62E-12	TP53 mutation status	
Normal-vs-Age(61-80Yrs)	<1E-12	Normal-vs-TP53-Mutant	1.62E-12
Normal-vs-Age(81-100Yrs)	1.59E-04	Normal-vs-TP53-NonMutant	<1E-12
Age(21-40Yrs)-vs-Age(41-60Yrs)	6.98E-01	TP53-Mutant-vs-TP53-NonMutant	9.66E-01
Age(21-40Yrs)-vs-Age(61-80Yrs)	5.40E-01		

Supplementary Table 2. Expression of different subgroups of *ARHGAP30* protein.

Comparison	Statistical significance	Comparison	Statistical significance
Sample types		Age(41-60Yrs)-vs-Age(61-80Yrs)	6.09E-03
Normal-vs-Primary	2.03E-08	Age(41-60Yrs)-vs-Age(81-100Yrs)	3.89E-01
Individual cancer stages		Age(61-80Yrs)-vs-Age(81-100Yrs)	6.12E-01
Normal-vs-Stage1	9.45E-05	Patient's weight	
Normal-vs-Stage2	4.59E-05	Normal-vs-Normal Weight	3.09E-07
Normal-vs-Stage3	1.49E-02	Normal-vs-Extreme Weight	6.86E-02
Normal-vs-Stage4	NA	Normal-vs-Obese	4.74E-02
Stage1-vs-Stage2	1.95E-01	Normal-vs-Extreme Obese	5.93E-01
Stage1-vs-Stage3	9.76E-01	Normal Weight-vs-Extreme Weight	6.60E-02
Stage1-vs-Stage4	NA	Normal Weight-vs-Obese	6.49E-01
Stage2-vs-Stage3	2.94E-01	Normal Weight-vs-Extreme Obese	8.59E-01
Stage2-vs-Stage4	NA	Extreme Weight-vs-Obese	4.18E-01
Stage3-vs-Stage4	NA	Extreme Weight-vs-Extreme Obese	8.34E-01
Patient's race		Obese-vs-Extreme Obese	9.64E-01
Normal-vs-Caucasian	3.61E-02	Tumor's grade	
Normal-vs-African American	NA	Normal-vs-Grade1	6.90E-03
Normal-vs-Asian	NA	Normal-vs-Grade2	6.10E-05
Caucasian-vs-African American	NA	Normal-vs-Grade3	5.87E-04
Caucasian-vs-Asian	NA	Grade1-vs-Grade2	2.75E-01
African American-vs-Asian	NA	Grade1-vs-Grade3	6.04E-01
Patient's gender		Grade2-vs-Grade3	<1E-12
Normal-vs-Male	2.68E-05	Tumor histology	
Normal-vs-Female	3.91E-06	Normal-vs-Lepidic adenocarcinoma	1.99E-01
Male-vs-Female	2.29E-01	Normal-vs-Papillary adenocarcinoma	9.59E-02
Patient's age		Normal-vs-Squamous cell carcinoma	NA
Normal-vs-Age(21-40Yrs)	9.32E-02	Normal-vs-Adenocarcinoma	5.52E-04
Normal-vs-Age(41-60Yrs)	9.87E-08	Normal-vs-Colloid adenocarcinoma	NA
Normal-vs-Age(61-80Yrs)	1.25E-03	Normal-vs-Acinar adenocarcinoma	1.58E-03
Normal-vs-Age(81-100Yrs)	9.39E-01	Normal-vs-Solid adenocarcinoma	6.70E-02
Age(21-40Yrs)-vs-Age(41-60Yrs)	6.06E-01	Normal-vs-Other	2.70E-03
Age(21-40Yrs)-vs-Age(61-80Yrs)	1.93E-01	Papillary adenocarcinoma-vs-Other	4.01E-01
Age(21-40Yrs)-vs-Age(81-100Yrs)	2.93E-01	Adenocarcinoma-vs-Other	2.56E-01